SG11201809671PA - Imidazolone compounds as human neutrophil elastase inhibitors - Google Patents

Imidazolone compounds as human neutrophil elastase inhibitors

Info

Publication number
SG11201809671PA
SG11201809671PA SG11201809671PA SG11201809671PA SG11201809671PA SG 11201809671P A SG11201809671P A SG 11201809671PA SG 11201809671P A SG11201809671P A SG 11201809671PA SG 11201809671P A SG11201809671P A SG 11201809671PA SG 11201809671P A SG11201809671P A SG 11201809671PA
Authority
SG
Singapore
Prior art keywords
international
chiesi
palermo
co7d
parma
Prior art date
Application number
SG11201809671PA
Inventor
Jonathan Mark Sutton
Robert Andrew Heald
Andrew Stephen Robert Jennings
Carmelida Capaldi
Elisabetta Armani
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of SG11201809671PA publication Critical patent/SG11201809671PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIP0 I PCT 0111111010 0111 inn III DID Immo mil no iflo lII oimiE (10) International Publication Number WO 2017/207430 Al (51) International Patent Classification: CO7D 403/04 (2006.01) CO7D 417/14 (2006.01) CO7D 413/14 (2006.01) A61K 31/4178 (2006.01) C07D 403/14 (2006.01) A61P 11/00 (2006.01) (21) International Application Number: Published: — with international search report (Art. 21(3)) PCT/EP2017/062754 (22) International Filing Date: 26 May 2017 (26.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16172196.4 31 May 2016 (31.05.2016) EP (71) Applicant: CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, 43122 PARMA (IT). (72) Inventors: SUTTON, Jonathan Mark; c/o CHIESI FAR- MACEUTICI S.p.A., Via Palermo, 26/A, 43122 PAR- MA (IT). HEALD, Robert Andrew; c/o CHIESI FAR- MACEUTICI S.p.A., Via Palermo, 26/A, 43122 PAR- MA (IT). JENNINGS, Andrew Stephen Robert; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). CAPALDI, Carmelida; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PAR- MA (IT). ARMANI, Elisabetta; c/o CHIESI FARMA- CEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). (74) Agent: MINOJA, Fabrizio; BIANCHETTI BRACCO MINOJA S.R.L., Via Plinio, 63, 20129 MILANO (IT). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 71' KM, ML, MR, NE, SN, TD, TG). O N 1-1 (54) Title: IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS \" (57) : This invention relates to imidazolone derivatives having human neutrophil elastase inhibitory properties, and their use 0 in therapy. (81)
SG11201809671PA 2016-05-31 2017-05-26 Imidazolone compounds as human neutrophil elastase inhibitors SG11201809671PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172196 2016-05-31
PCT/EP2017/062754 WO2017207430A1 (en) 2016-05-31 2017-05-26 Imidazolone compounds as human neutrophil elastase inhibitors

Publications (1)

Publication Number Publication Date
SG11201809671PA true SG11201809671PA (en) 2018-12-28

Family

ID=56096538

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912143UA SG10201912143UA (en) 2016-05-31 2017-05-26 Imidazolone compounds as human neutrophil elastase inhibitors
SG11201809671PA SG11201809671PA (en) 2016-05-31 2017-05-26 Imidazolone compounds as human neutrophil elastase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912143UA SG10201912143UA (en) 2016-05-31 2017-05-26 Imidazolone compounds as human neutrophil elastase inhibitors

Country Status (25)

Country Link
US (2) US9802919B1 (en)
EP (1) EP3464273B9 (en)
JP (1) JP6990663B2 (en)
KR (1) KR102404031B1 (en)
CN (1) CN109311850B (en)
AR (1) AR108610A1 (en)
AU (1) AU2017272405C1 (en)
BR (1) BR112018074608B1 (en)
CA (1) CA3020435A1 (en)
CL (1) CL2018003417A1 (en)
CO (1) CO2018012479A2 (en)
EA (1) EA036456B1 (en)
GE (1) GEP20207130B (en)
IL (1) IL263089B (en)
MX (1) MX2018014145A (en)
MY (1) MY195210A (en)
NZ (1) NZ747313A (en)
PE (1) PE20190176A1 (en)
PH (1) PH12018502242A1 (en)
SA (1) SA518400429B1 (en)
SG (2) SG10201912143UA (en)
TW (1) TWI738786B (en)
UA (1) UA123109C2 (en)
WO (1) WO2017207430A1 (en)
ZA (1) ZA201806743B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220034739A (en) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof
MX2021014443A (en) 2019-05-31 2022-01-06 Ikena Oncology Inc Tead inhibitors and uses thereof.
CN114650819A (en) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 Avermectistat for treating graft rejection, bronchiolitis obliterans syndrome and graft-versus-host disease
IL297211A (en) 2020-04-16 2022-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
WO2023115043A1 (en) * 2021-12-16 2023-06-22 Orixa Therapeutics Llc Small molecule inhibitors of pr3 and hne and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
JPWO2003031414A1 (en) * 2001-10-03 2005-01-20 日本曹達株式会社 Novel heterocyclic compounds and anti-inflammatory drugs
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
DE102009043260A1 (en) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolone derivatives
WO2011039528A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
JP2013177318A (en) * 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd Dihydropyrimidinone derivative and pharmaceutical use thereof
IN2015DN00202A (en) * 2012-07-12 2015-06-12 Chiesi Farma Spa
DK2935274T3 (en) 2012-12-18 2018-11-26 Chiesi Farm Spa 3-OXO-2,3,5,8-TETRAHYDRO- [1,2,4] TRIAZOLO [4,3-A] PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AIR TRACT
JP5799117B2 (en) * 2013-02-05 2015-10-21 大日本住友製薬株式会社 Pharmaceuticals consisting of uracil derivatives
KR20160097227A (en) 2013-12-16 2016-08-17 키에시 파르마슈티시 엣스. 피. 에이. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
US9409870B2 (en) * 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds

Also Published As

Publication number Publication date
MY195210A (en) 2023-01-11
AU2017272405A1 (en) 2018-11-22
US10023558B2 (en) 2018-07-17
TW201808934A (en) 2018-03-16
CA3020435A1 (en) 2017-12-07
KR102404031B1 (en) 2022-06-02
PH12018502242A1 (en) 2019-08-19
SG10201912143UA (en) 2020-02-27
JP2019520313A (en) 2019-07-18
MX2018014145A (en) 2019-03-11
NZ747313A (en) 2020-01-31
EP3464273B1 (en) 2020-04-08
JP6990663B2 (en) 2022-01-13
SA518400429B1 (en) 2021-09-22
US9802919B1 (en) 2017-10-31
WO2017207430A1 (en) 2017-12-07
UA123109C2 (en) 2021-02-17
CO2018012479A2 (en) 2018-12-14
AU2017272405B2 (en) 2020-09-10
CN109311850B (en) 2021-11-19
IL263089B (en) 2021-12-01
CN109311850A (en) 2019-02-05
AU2017272405C1 (en) 2021-01-14
GEP20207130B (en) 2020-07-10
PE20190176A1 (en) 2019-02-01
BR112018074608A2 (en) 2019-03-19
EA036456B1 (en) 2020-11-12
ZA201806743B (en) 2020-02-26
CL2018003417A1 (en) 2019-01-18
US20180009787A1 (en) 2018-01-11
EP3464273B9 (en) 2020-10-21
BR112018074608B1 (en) 2024-01-23
TWI738786B (en) 2021-09-11
KR20190015232A (en) 2019-02-13
AR108610A1 (en) 2018-09-05
IL263089A (en) 2018-12-31
EP3464273A1 (en) 2019-04-10
EA201892714A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
SG11201809671PA (en) Imidazolone compounds as human neutrophil elastase inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201907034PA (en) Methods of treating influenza
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809702SA (en) Benzenesulfonamide compounds and their use as therapeutic agents
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201909841RA (en) Antitumoral compounds
SG11201907217RA (en) Pharmaceutical combinations for treating cancer
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer